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Lungs with primary graft dysfunction (PGD) are characteristically edematous and have
reduced compliance and impaired gas exchange. PGD is often attributed to ischemia–
reperfusion injury (IRI). Because IRI has been shown to cause alterations in the integrity of
the endothelial barrier and alveolar epithelial capacity to resorb fluid,1,2 every transplanted
lung is at risk of developing edema if there is any elevation of pulmonary venous pressure,
either due to mechanical problems or left ventricular dysfunction. Previously, PGD has been
attributed to events in the recipient, but pre-existing inflammatory status of the donor lung
before recovery may also impact the development of PGD, as has been observed in braindead donors or donors after circulatory death.3,4 Aside from early graft dysfunction, PGD is
critically important due to its impact on long-term survival, because of the increased risk of
bronchiolitis obliterans syndrome (BOS).5,6
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Our current theoretical understanding of the molecular triggers of PGD can be traced to
ideas proposed by Polly Matzinger over 20 years ago.7 In her “Danger Hypothesis,” she
proposed that endogenous substances (now categorized as damage-associated molecular
patterns [DAMPs]) released from injured cells would promote innate immune responses that
can prevent allograft survival.8 Janeway and Medzhitov showed that DAMPs, along with
pathogen-associated molecule patterns (PAMPs), are recognized by pattern recognition
receptors (PRRs) that, when engaged, stimulate inflammatory gene expression.9 Later
reports showed DAMP accumulation and the involvement of PRR signaling pathways in
PGD patients, but precisely how they contribute to this type of acute lung injury remains an
active area of investigation,3,10,11 as lung IRI also may be influenced by PAMPs derived
from the gut microbiota.12 In addition, the recent availability of multicenter-derived lung
transplant recipient outcome data in conjunction with transcriptome and genomic analysis
and new experimental approaches has identified additional mechanisms that could promote
PGD. This has led to new insights into the role of the lung parenchyma, myeloid cells,
lymphocytes, inflammatory mediators and autoreactive lung proteins. Moreover, there have
been recent discoveries on how tissue inflammation is resolved, which, when applied to
PGD, may provide the basis for the development of novel therapies. Herein we review the
cellular and molecular mechanisms that mediate PGD.

Epithelium and endothelium

Author Manuscript

The inability to maintain and repair homeostatic barriers that promote pulmonary function,
namely airway epithelium and vascular endothelium, is thought to play a key role in PGD.
RNA transcript profiling experiments performed on 50 lungs before implantation analyzed
differentially expressed transcripts between recipients with Grade 3 PGD at time of return to
the intensive care unit (T0) and those that were Grade 0 PGD at T0.13 Of those 50 recipients,
16 developed PGD Grade 3 at T0 and 34 were PGD negative at T0. Twenty-three genes were
increased and 42 were decreased in the PGD group. A number of gene networks were
identified that were involved in apoptosis and cellular stress responses. Metallothionein 3
mRNA expression levels were higher in donor lungs that did not develop PGD. Those data
suggest that donor lungs with more intact anti-oxidant defense and with a greater capability
to support epithelial wound repair may be protected from PGD. However, because T0 PGD
development may be related to intra-operative management, further studies will be needed to
determine whether such gene expression patterns are linked to PGD severity at 72 hours
post-transplant.

Author Manuscript

Collagen Type V (Col-V) is a constituent of the extracellular matrix and is usually hidden
from exposure to the host immune system because it is contained entirely within Collagen
Type I fibrils. Damage to the collagen structure in the lung can lead to exposure of Col-V,
allowing it to act as a cryptic antigen that leads to autoimmunity against Col-V and a
delayed-type hypersensitivity reaction. It has been suggested that pre-formed antibodies to
Col-V in patients with advanced lung disease may predispose that individual to develop
PGD after lung transplantation.14 Fifty-five patients awaiting lung transplant were
investigated to assess their memory T-cell responses to Col-V. Sixteen had positive
responses to Col-V. The positivity was much more frequent among idiopathic pulmonary
fibrosis (IPF) patients (58.8%) compared to patients without IPF (15.8%). In a univariate
J Heart Lung Transplant. Author manuscript; available in PMC 2018 April 01.
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analysis, T-cell responses to Col-V were associated with an increased risk of developing
PGD. That study suggested that epithelium and endothelium basement membrane disruption
in the donor lung may act as a trigger for T-cell–mediated immune responses in recipients
pre-sensitized to Col-V.
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Although endothelium and alveolar epithelium are targets of injury, they can also be sources
of inflammatory mediators that may promote PGD. For example, studies have shown that
ischemia, as a consequence of donor lung procurement, is mechanically sensed by
endothelial cells, which respond by producing reactive oxygen species and nitric oxide that
initiate pre-transplant tissue injury.15,16 The US Lung Transplant Outcomes Group
compared plasma levels of 25 cytokines and chemokines in 25 recipients with Grade 3 PGD
at 72 hours compared to 25 recipients without PGD at any time-point from 6 hours to 72
hours as a nested case-control study.17 A multivariable logistic regression analysis showed
that PGD cases had higher circulating levels of the chemokines monocyte chemoattractant
protein-1/CC motif chemokine 2 (MCP-1/CCL2) and IP-10/CXC ligand 10, which can be
secreted by activated endothelial cells and alveolar epithelial cells. That report suggested
that an early chemotactic signal for monocytes and lymphocytes was present in lungs with
PGD and that the activated endothelial or epithelial surfaces may have contributed to that
signal. Notably, despite observations that cultured bronchial epithelial cells isolated from
chronically rejected lung transplant recipients produced high amounts of inflammatory
mediators,18 it remains to be determined whether bronchial epithelium plays a direct role in
IRI-mediated cytokine production in PGD patients.
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Toll-like receptor expression (TLR) on lung parenchymal cells may also play a major role in
exacerbating PGD.19 TLR4, a PRR sensor for lipopolysaccharide (LPS) and damageassociated molecular patterns released by injured cells, triggered early and sustained edema
on non-bone-marrow-derived cells along with early activation of mitogen-activated protein
kinases (MAPKs) and nuclear factor-kappaB (NF-κB) in a murine model of lung IRI.
Endothelial cells subjected to simulated cold IRI suggested the possibility that edema due to
IRI may be due to endothelial cell cytoskeletal alteration, thus leading to inter-endothelial
cell gap formation during ischemia. Simulated reperfusion resulted in activation of MAPKs
and NF-κB and expression of interleukin (IL)-6 and IL-8 by endothelial cells.20 In addition,
in a cell culture model of simulated warm ischemia, inter-endothelial cell gap formation was
prevented by a competitive TLR4 antagonist, implicating a direct link between pulmonary
edema and TLR signaling.19
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Angiotensin II (AngII) signaling has been implicated in the pathogenesis of pulmonary
fibrosis. Moreover, inhibition of renin–angiotensin signaling has been shown to ameliorate
experimental fibrous airway obliteration. In one study, there was an acute increase in plasma
AngII and matrix metalloproteinase-9 (MMP-9) expression after lung transplantation, with a
corresponding rise in angiotensin receptor 2 (ATR2) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) expression on epithelial cells recovered from bronchoalveolar lavage
fluid.21 Those data indicate that pro-fibrotic signals induced by ischemia-reperfusion and
cardiopulmonary bypass may impair recovery of epithelial cell integrity.

J Heart Lung Transplant. Author manuscript; available in PMC 2018 April 01.
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Pulmonary surfactant proteins produced by Type II pneumocytes are known to have major
functions in host defense and lung immune homeostasis. Recipients of lung allografts with
low levels of surfactant protein A (SP-A) mRNA expression before implantation had an
increased incidence of Grades 2 or 3 PGD, higher 30-day mortality, and a greater likelihood
of developing chronic lung allograft dysfunction (CLAD) or causing death within 24 months
of transplant.22 Specifically, donor lungs with SP-A2 genotype 1A1A0 had the lowest level
of SP-A messenger RNA (mRNA) expression.
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The Clinical Trials in Organ Transplantation investigators sought to identify key pathways
mediating PGD by comparing pre- and post-transplant donor lung bronchoalveolar lavage
fluid (BALF) mRNA expression profiles in lung recipients who developed Grade 3 PGD
versus controls matched for diagnosis and donor age who did not develop PGD.23
Differential expression and gene set enrichment analysis identified inflammation activation
and innate immune signaling via TLR pathways as major contributors to the pathogenesis of
PGD. Those findings indicated an early innate immune signal in the lung, perhaps in
response to inflammatory cytokines or DAMPs released by injured epithelial and endothelial
cells.

Alveolar macrophages
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PGD classically has been thought to be a biphasic process, with the first phase determined
by donor cells and donor characteristics, whereas the infiltrating recipient cells were
responsible for the second phase, which occurred within hours of reperfusion. The alveolar
macrophage (AM) has been a known source of cytokines and oxidants in many models of
acute inflammatory lung injury. AM depletion or inactivation reduced IRI in animal
models.24–26 After ischemia and 15 minutes of reperfusion, tumor necrosis factor-alpha
(TNF-α) and IL-1β localized to the AM and the early release allowed the AM to enhance
the activation of other lung cell types.27–29 Therefore, AM activation and downstream
signaling have been shown to be critical in the coordination and amplification of
inflammatory signaling and development of lung reperfusion injury. More recently, the
critical importance of TLR signaling in AM early in lung IRI has been recognized. Although
the activating ligand is not yet known, within 15 minutes of reperfusion TLR4, through a
signaling pathway that is dependent on the adapter protein myeloid differentiation factor 88
(MyD88), promoted MAPK activation, nuclear translocation of NF-κB and transcriptional
upregulation of inflammatory mediators.30 The same changes also occurred when AMs were
isolated in culture and subjected to hypoxia and reoxygenation. The use of short-interfering
RNA to knock down TLR4 expression in the AM markedly reduced the AM response to
oxidative stress in vivo and in vitro.31 That signaling paradigm can be manipulated to take
advantage of the dual nature of TLR4 signaling in the AM and provide protection from lung
reperfusion injury. Low-dose LPS (which does not induce lung injury independently) can be
administered to experimental animals intratracheally before lung ischemia and result in nonischemic pre-conditioning. Such LPS pre-treatment would inhibit AM TLR4 signaling
through MyD88-dependent and -independent signaling pathways that utilize the adapter
molecules toll-like/IL-1 receptor-domain-containing, adapter-inducing interferon-β (TRIF),
and TRIF-related adapter molecule. The result enhanced AM production of interferon (IFN)γ and IL-10, reduced production of TNF-α and IL-1β and promoted lung protection.32
J Heart Lung Transplant. Author manuscript; available in PMC 2018 April 01.
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Notably, those findings from experimental models of lung IRI are consistent with recent
human genomic studies of PGD.11,23

Neutrophils

Author Manuscript

Neutrophilia is thought to play a critical role in PGD.33 However, how neutrophils regulate
PGD severity remains to be defined. The bulk of our understanding of this relationship has
come from experimental lung injury models showing that the initial recruitment of
neutrophils was triggered by DAMP release.34–37 As suggested by the “Danger Hypothesis”
noted earlier, DAMPs stimulated cognate PRRs to induce the expression of ELR+ CXC
chemokines and IL-1β, both of which were found to promote expression of adhesion
molecules on the luminal surface of vascular endothelium to stimulate neutrophil
transendothelial migration into interstitial tissues.38 In particular, early expression of
IL-17,39 a well-established stimulator of ELR+ CXC chemokines,40 may play a critical role
in early neutrophil graft sequestration.34 In a lung warm-ischemia model, the DAMP highmobility group box 1 (HMGB1) protein was recently shown to stimulate PRR, the receptor
for advanced glycation products (RAGE) on invariant natural killer T cells, to produce IL-17
and result in pulmonary neutrophilia. Consistent with these observations were reports
showing that having either elevated RAGE plasma levels or carrying certain IL-17 receptor
polymorphisms increased the risk for PGD.10,41

Author Manuscript

Grommes and Soehnlein showed that, after entry into the lung, neutrophils released reactive
oxygen species (ROS), serine proteases, cationic peptides and MMPs that catalyzed the
breakdown of homeostatic barriers that regulate blood gas exchange.42 For example, ROS
have been shown to disrupt endothelial cell tight junctions and induce the necrosis of
alveolar Type II cells, whereas the serine protease neutrophil elastase and the cationic
peptide LL-37 have been shown to trigger epithelial cell apoptosis.43,44 In addition, MMPs,
such as MMP-8, degraded the pulmonary collagen matrix.45,46 In addition to directly
inflicting parenchymal tissue damage, neutrophils may promote PGD by directly inhibiting
gas exchange through the expulsion of nuclear chromatin within the capillary lumen.47 The
structures known as neutrophil extracellular traps (NETs) have recently been shown to
accumulate in PGD patients.48
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Given that the role of neutrophils in PGD is likely very complex, there has been considerable
interest in developing better models of this injury. Introduction of the fully aerated and
vascularized mouse orthotopic lung transplant (mOLT) model, which allows for the practical
use of genetic dissection and transgene techniques, along with development of intravital lung
2-photon microscopy to visualize and quantitate leukocyte trafficking, has led to new
insights into how neutrophils promote inflammatory responses after lung
transplantation.49,50 Importantly, when the mOLT was used to model PGD, there was a
replication of the clinical scenario of neutrophilia, poor graft function and edema.51 Partial
antibody-mediated depletion of neutrophils helped restore lung graft function and reduced
tissue damage and inflammatory gene expression.52 That property of the model has led to
further insights into how neutrophils promote PGD. These included the demonstration that
the co-transcriptional factor B-cell lymphoma 3–encoded protein and the inhibitory κβ
kinase β were negative regulators of lung transplant-mediated IRI through limiting
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emergency granulopoiesis and attenuating neutrophil chemotactic mediator expression,
respectively.52,53 In addition, neutrophil extravasation into graft interstitium was shown,
unexpectedly, to be dependent on inflammatory monocytes,50 and intragraft neutrophils
were observed making physical, prolonged contact with antigen-presenting cells to stimulate
IL-12 expression and alloreactive Th1 cell expansion, suggesting a mechanism linking PGD
to rejection.54 These data, taken collectively, may explain clinical reports of high levels of
monocyte chemoattractants and IL-12 in PGD patients and the association between
neutrophilia and rejection.17,55 Finally, the role of NETs in PGD patients was recently
investigated using that model.48 Analogous to PGD patients, NETs were shown to
accumulate in mOLT grafts. However, when mOLT recipients were treated with DNAse,
pulmonary function improved significantly, suggesting a potential therapeutic approach for
PGD.
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Although neutrophils are predominantly recognized for their pro-inflammatory role in PGD,
recent work has suggested that some level of neutrophilia is required to resolve tissue injury.
For example, neutrophil swarming, which has been observed in lung transplant models of
PGD, was reported to promote wound healing that will seal off damaged tissue.50 In
addition, neutrophils through their own apoptotic death were found to play a critical role in
re-establishing lung homeostasis after injury through the subsequent phagocytic uptake of
their carcasses by lung macrophages.56 The clearance of apoptotic cells, efferocytosis,
inhibited the production of IL-12 and induced the expression of anti-inflammatory mediators
such as IL-10,57 a cytokine shown to promote the functional repair of human donor lungs
when expressed ectopically.58 Future studies are needed to determine whether augmenting
neutrophil efferocytosis may be useful as a therapeutic strategy to prevent PGD.

Author Manuscript

Lymphocytes
In a single lung transplant rat model, preservation with Perfadex solution primed with
thioredoxin (Trx) showed significantly better graft function and attenuation of infiltration of
macrophages and cytotoxic T cells compared with rats not primed with Trx.59 In mice,
comparable and significant protection from lung dysfunction and injury occurred after
antibody depletion of neutrophils or CD4+ T cells but not CD8+ T cells. Lung IRI was
proportional to the infiltration of pulmonary neutrophils (PMNs) but not T cells. Moreover,
PMN infiltration and the production of CXCL1/KC were significantly diminished by CD4+
T-cell depletion but not vice versa. That study suggested that PMNs mediated IRI; however,
CD4+ T cells played a critical role in stimulating chemokine production and were
responsible for neutrophil chemotaxis into the lung at the time of reperfusion.60

Author Manuscript

In a syngeneic rat lung transplant model,61 recipient CD4+ T cells infiltrated lung grafts
within 1 hour of reperfusion and upregulated the expression of CD25 over the ensuing 12
hours. After 12 hours of reperfusion, recipient nude rats demonstrated significantly better
oxygenation and lower peak airway pressures than recipient heterozygous rats. The effect of
T cells was independent of neutrophil recruitment and activation in the transplanted lung.
The results demonstrated that recipient CD4+ T cells were activated and mediated lung
injury 12 hours after lung transplantation in that model. The proliferation of the T cells was
antigen-independent and is known as bystander activation.

J Heart Lung Transplant. Author manuscript; available in PMC 2018 April 01.
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As noted earlier, pre-transplant activation of recipient immunity to Col-V may play a role in
PGD after transplantation. Th17- and monocyte-dependent immunoreactivity directed
toward Col-V has been associated with poor early lung allograft function and that reactivity
was mediated by CD4+ T cells and monocytes. That finding supported the concept that
humoral, as well as cell-mediated, immunity to Col-V is a risk factor for PGD, and that preformed anti-Col-V antibodies have a key role in this process.14,62 Finally, increases in
MCP-1 and CXCL10 in plasma of patients developing PGD, compared with controls,
suggested that IFN-induced pathways resulted in accumulation of effector T cells in the
allograft via CXCR3.60

Resolution and repair mechanisms

Author Manuscript

Although identification of the mechanisms of PGD mechanisms has been informative,
translation to clinically effective therapies has been limited. This has led to increased interest
into uncovering the determinants of resolution and repair after PGD. Resolution is not
simply a passive process from removal of the initial insult and exhaustion of early
inflammatory cells, but rather an active process. Resolution of PGD involves cellular and
molecular pathways that involve: (a) removal of apoptotic neutrophils by macrophages; (b)
reabsorption of protein and alveolar fluid; (c) repair of damaged endothelial and epithelial
barrier; and (d) gradual clearance of extracellular matrix and fibrosis.
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T lymphocytes have been ascribed, as a whole, to promote IRI,60 but more recent work has
shown that a small fraction of CD4+ T cells, known as regulatory CD4+ T cells (Tregs), may
play an opposite role.63 Identified by the expression of the master transcription factor
forkhead box protein 3, Tregs promoted the maintenance of immunologic self-tolerance by
suppressing aberrant or excessive immune responses that are harmful to the host.64,65 That
function has been ascribed to inhibiting antigen-dependent responses, including
experimental studies of immunosuppression-mediated lung transplant tolerance.66–68
However, Tregs also have been reported to resolve experimental acute lung injury by
inhibiting macrophage pro-inflammatory responses through augmenting neutrophil
efferocytosis.69 Moreover, they have been shown to limit fibroproliferation and augment
alveolar epithelial repair.70,71 Given their limited numbers, Tregs have been shown to
become highly proliferative after lung inflammation and are a key feature in controlling
exuberant immune responses.65,72 Ongoing clinical trials are evaluating the role of Tregs in
solid-organ transplantation.73 Studies by Neujahr et al and Bhorade et al have shown that a
decreased proportion of Foxp3+ cells among CD4 cells in bronchoalveolar lavage (BAL) can
potentially predict worse lung allograft outcome and help guide therapeutic
immunosuppression in lung transplant recipients.74,75 However, another group found that
lung Tregs increased in the setting of acute rejection and declined in numbers in patients
with quiescence of rejection.76 Therefore, the functional role of Tregs in humans with PGD
remains elusive and there is a need to evaluate functional suppressive assays and rigorously
phenotype sub-populations of Tregs in patients with PGD.
Other studies have suggested additional approaches to promote the resolution of PGD.
Those studies included the recognition that resolution of tissue inflammation is a
biosynthetically active process dependent on the synthesis of pro-resolving lipid
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mediators.77 One such molecule, lipoxin A4, has been detected in lung transplant recipient
BAL and has known potent inhibitory effects on neutrophil transendothelial migration.78
Another lipid mediator, reslovin E1, was demonstrated to promote human neutrophil
apoptosis and clearance of neutrophils from inflamed lungs in mice.79 Mesenchymal stem
cells (MSCs), multipotent non-hematopoietic cells found in bone marrow and fatty tissues,
have well-described immunosuppressive properties and have shown promise in ameliorating
both acute and chronic pulmonary inflammation.80 Of note, in a recent report, conditioned
media from bone-marrow-derived MSCs has been shown to induce Treg expansion and
inhibit pulmonary edema in an experimental lung IRI model.81 Promoting endothelial
integrity itself also may be a useful approach in combating PGD. Sphingosine 1-phosphate
(S1P), a biologically active lipid growth factor that is derived from the cell membrane lipid
component sphingosine, has been shown to bind to G-protein-coupled receptors that
promote endothelial cell integrity.82 Reports in several lung IRI models, including a lung
transplant-mediated IRI model, showed that FTY720, a functional analog of S1P, inhibited
neutrophil sequestration, prevented edema and promoted pulmonary function.83,84 In
addition, several pre-clinical studies have aimed at reducing tissue injury from ischemia and
reperfusion by limiting ROS-mediated tissue injury. For example, allopurinol reduces of
superoxide formation via inhibition of xanthine oxidase. Calcium channel blockers given to
lung donors before organ procurement reduce lipid peroxidation and endothelial
dysfunction, potentially limiting PGD. Iron chelators also limit lipid peroxidation and
hydroxyl radical formation. Inhibitors of P-selectin, intracellular adhesion molecule-1
(ICAM-1), C1 esterase, complement receptor 1 with selectin receptor (sialyl Lewis X),
platelet-activating factor (PAF) and endothelin have shown benefit during lung IRI85–92 and
may have similar effects in PGD. Inhibitors of complement receptor and PAF showed
reductions in PGD in randomized, controlled trials.93,94 Studies using ex vivo lung perfusion
systems will provide key translational data to facilitate development of new PGD therapies
in the near future.

Conclusions

Author Manuscript

The last 10 years of investigation into the underlying mechanisms of PGD have illuminated
important and novel roles for graft-infiltrating cells, graft-resident immune cells and
parenchymal cells. In particular, the use of experimental PGD models has led to a working
paradigm in which transplant-mediated innate immune signals generated by graft-resident
cells, such as endothelium, epithelium and alveolar macrophages, trigger the overexuberant
infiltration of monocytes, neutrophils and T cells. The crosstalk between these cells results
in the release of cytokines, reactive oxygen intermediates and proteolytic enzymes that break
down homeostatic barriers critical for lung graft function and the priming of adaptive
immune responses that prevent transplant survival. Notably, risk for PGD may not be just
intrinsically related to the graft, but may also be encoded into the recipient in the form of
immune system-related genetic polymorphisms or pre-existing cellular or humoral reactivity
to pulmonary autoantigens. However, the development of therapies to combat PGD
ultimately may lie in better understanding of the mechanisms that promote the resolution of
inflammation. Experimental models of acute lung injury and some clinical studies have
suggested that strategies utilizing Tregs, augmenting efferocytosis or ameliorating oxidative
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stress may be potential approaches to prevent or treat PGD. Although it appears that
multiple pathways trigger and exacerbate PGD, what remains to be determined is which
mechanisms are most important. To answer this question, it may be more advantageous to
reverse the normal process of mechanistic investigation—that is, first determining whether
observations from PGD patients can be reproduced in experimental models.
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